News

Express Scripts, Caremark and Optum Rx sued the FTC after the agency accused them of driving up the cost of insulin. But the countersuit is being put to bed now that the PBMs are settling with regulators.

CVS Heath's Siddharth ‘Sid’ Tenneti joins Ashley Mastronardi on NYSE Live to discuss their support for America250

CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 12.4% gain over the past six months, beating the S&P 500 by 5.6 percentage points.

Joel Greenblatt's Magic Formula ranks stocks on earnings yield and return on capital, but for retirees those two numbers can point straight toward disaster. Three stocks cleared the screen, and only one survives when income reliability and volatility enter the equation.

The stock is already up 30% this year.

Salesforce Inc. (NYSE:CRM) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, TD Cowen reaffirmed its $240 price objective and Buy rating on Salesforce Inc. (NYSE:CRM). The update came after the firm hosted an investor dinner with new IR Senior Director Lauren O’Brien and the Vice President of Investor Relations, Valmik […]

Pfizer's CFO joins Nike, Wendy's hires Potbelly Sandwiches' CFO, Airwallex's new CFO boomerangs back to the company and more.

CVS Health’s implied fair value has been updated from US$102.85 to US$105.38 per share, signaling a modest reset in how analysts are framing the stock. Behind this move, recent research highlights stronger engagement potential from GLP 1 programs, improving sentiment toward managed care, and an earnings story that some bullish analysts view as supported by margin recovery and policy visibility, even as more cautious voices flag ongoing risks. Keep reading to see what is driving this evolving...

Florida's Attorney General has opened an investigation into CVS Health's (NYSE:CVS) Caremark pharmacy benefit manager for alleged anticompetitive practices. The probe focuses on claims of steering patients, preferential reimbursement rates, and burdensome audits that may disadvantage independent pharmacies. The investigation centers on Caremark's role in managing prescription drug benefits and its interactions with pharmacies across Florida. CVS Health sits at the intersection of retail...

CI is evolving beyond traditional insurance, using AI, specialty pharmacy and healthcare services to drive growth and sharpen its business focus.

ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary.

(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a

CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

While analysts acknowledged incoming finance chief David Denton’s credentials, they also flagged his lack of activewear experience.

David Denton, who has led Pfizer's finances since 2022, will take over as Nike's chief financial officer on Aug. 17

Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.

The investigation by Florida’s attorney general comes as states look to check pharmacy benefit managers for allegedly driving up drug costs.

Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.

Florida’s attorney general says he is examining whether CVS’s pharmacy benefit manager steers patients to its own pharmacies.

CVS Health Corporation (NYSE:CVS) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. The New York Times, in an article published on June 11, 2026, pointed to two federal reports from the Department of Health and Human Services and stated that CVS Health Corporation (NYSE:CVS) and other major Medicare Advantage […]

It's expanding its scope of services for GLP-1 obesity medications.

Clover Health Investments, Corp. (NASDAQ:CLOV) was among the stocks on Jim Cramer’s radar on Mad Money, as he advised investors to care about where a stock is going, not where it has been. A caller referenced Cramer’s previous comment, calling it speculative, and noted that the company reported GAAP profitability in Q1 2026 and guided […]

Does CVS Health (CVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

CVS Health is rolling out a first of its kind aluminum bottle for store branded over the counter products across its national pharmacy network. The company is also funding mobile maternal health clinics in underserved rural areas of Missouri, focused on prenatal and mental health services. These moves expand CVS Health’s sustainability and community health efforts beyond its core retail and insurance operations. For investors watching NYSE:CVS, these announcements add context around how the...

Former CEOs of Humana and CVS Health have been appointed as advisors to Optura, an AI focused healthcare startup. UnitedHealth Group (NYSE:UNH) is participating on the advisory side, aligning with efforts to measure and optimize return on AI investment in healthcare. The collaboration brings together major US health insurers and service providers around a shared AI platform approach. For UnitedHealth Group, a large diversified health insurer and services company, this move puts more focus...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at CVS Health (NYSE:CVS) and its peers.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Dave Denton will leave in August as Pfizer works through its post-COVID reset.

Long before the stock surged, the company had been openly broadcasting its decision to choose profit over scale. The market initially ignored the signal - until the turnaround became undeniable.